ESR1 and breast cancer: Methylation of the HIN-1/RASSFIA panel was strongly correlated to positive ER, PR, and HR expression; 88% of HIN-1/RASSFIA-positive breast cancers were ER-positive and only 12% of breast cancers were ER-negative (p < 0.001).